Strategic Partners for the Evaluation of Predictive Signatures of Prostate Cancer (SPECS)
Grants Funding in Association with SPECS
$35,000/year from 2P30 CA-62203-14 (Meyskens); 08/01/02-01/31/09
NIH/NCI - University of California, Irvine -- $1,724,690
Cancer Center Support Grant
$33,000/year from Subcontract from UCSD (G. Saxe); 08/19/08-07/31/11
University of California, Irvine -- $450,000
$40,000 from United Kingdom, UCI Award No. UK-43982 (Mercola); 02/06/08-02/06/09 Phase I:
"Feasibility Study for the Prediction of Outcome of Prostate Cancer"
Applications Pending
Department of Defense Congressionally Directed Medical Research – Synergy Idea Award pre-submission 5/08: “Molecular Network And Cell Signaling Analysis Of Prostate Cancer Tissue Provides A Rational Determination Of Biomarkers For Disease Recurrence: A Systems Biology Approach” - $750,000 Co-investigators: Chung Lee, NWU; Emanuel Petricoin, GWU.
Department of Defense Congressionally Directed Medical Research, PC081259 – Synergy Idea Award pre-submission 6/08: “Molecular Network and Cell Signaling Analysis Of Prostate Cancer” - $750,000 Co-investigators: Michael Lilly, UCI.
SBIR: Proveri Inc. (M. Berg, P.I.) with Burnham Institute for Medical Research
(S. Krajewski, site P.I), Phase I application 9/25/08: “Development of Antibody Biomarkers that are Predictive of the Outcome of Prostate Cancer.”
National Institutes of Health. - $ 225,000 Phase I, 12/1/08 – 11/30/09.
SBIR: Proveri Inc. (M. Berg, P.I.) with Burnham Institute for Medical Research
(S. Krajewski, site P.I), Phase I application 7/22/08: “Development of a Multi-antibody Panel for an Immunohistochemistry Based Assay of Biomarkers Predictive of the Outcome of Prostate Cancer. ”
National Institutes of Health. - $ 243,000 Phase I, 3/1/09 – 2/28/10.
SBIR: Proveri Inc. (M. Berg, P.I.) with Vala Sciences Inc. (J. Price, CEO and site P.I) Phase I application, 11/3/08 “Development of a Multiplex Antibody Assay using Automated Immunofluorescence Assay for the Predictive of the Outcome of Prostate Cancer.”
National Institutes of Health. - $ 225,000 Phase I, 12/1/08 – 11/30/09.
SBIR: Althea Technologies Inc (J. Monforte, P.I.) and UCI (D. Mercola site P.I.), Phase I Application, 7/22/08. “Validation of a Prostate Cancer Prognostic Test”.
National Institutes of Health - $ 265,000 Phase I, 12/1/08 – 11/30/09.